Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vertex PharmaceuticalsMEX:VRTX +1.78%88 Net Cash per Share is MXN46.63 as of Jun. 2026, which is 100% below its 10-year median of 23.72. GuruFocus rates MEX:VRTX with a GF Score™ of 88/100 and a GF Value™ of MXN8,672.74 (Fairly Valued). The stock has 5 warning signs investors should review. Among 774 Biotechnology companies, Vertex Pharmaceuticals ranks worse than 98.58% on this metric.
Vertex Pharmaceuticals (MEX:VRTX) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Vertex Pharmaceuticals Net Cash per Share Related Terms
Vertex Pharmaceuticals Net Cash per Share Historical Data
* Premium members only.
The historical data trend for Vertex Pharmaceuticals's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:VRTX vs REGN, RVMD, ALNY: Net Cash per Share Comparison
For the Biotechnology subindustry, Vertex Pharmaceuticals's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vertex Pharmaceuticals Price-to-Net-Cash vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Vertex Pharmaceuticals's Price-to-Net-Cash falls into.
Vertex Pharmaceuticals Net Cash per Share Calculation
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Vertex Pharmaceuticals's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vertex Pharmaceuticals (MEX:VRTX) has a Net Cash per Share of MXN46.63 as of Jun. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Vertex Pharmaceuticals and its competitors. This is 97% above median its historical median of 23.72. Over the past decade, Vertex Pharmaceuticals' Net Cash per Share has ranged from 11.35 to 911.31. According to the industry distribution chart, Vertex Pharmaceuticals ranks #763 out of 774 companies in the Biotechnology industry, placing it in the top 98.6%.
Is Vertex Pharmaceuticals' Net Cash per Share too high?
Vertex Pharmaceuticals' current Net Cash per Share of MXN46.63 is 97% above median its 10-year median of 23.72. Over the past 10 years, this metric has ranged from a low of 11.35 to a high of 911.31. Based on the distribution chart, Vertex Pharmaceuticals ranks #763 out of 774 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Vertex Pharmaceuticals has a GF Score™ of 88/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vertex Pharmaceuticals' Net Cash per Share compare to REGN and RVMD?
According to the Biotechnology industry distribution chart, Vertex Pharmaceuticals ranks #763 out of 774 companies for Net Cash per Share. This places Vertex Pharmaceuticals in the lower half of its industry. The industry median Net Cash per Share is 5.23. Historically, Vertex Pharmaceuticals' own Net Cash per Share has ranged from 11.35 to 911.31 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Biotechnology company?
The median Net Cash per Share among Biotechnology companies is 5.23, based on 774 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Vertex Pharmaceuticals and its competitors. For the Biotechnology industry, the median Net Cash per Share is 5.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vertex Pharmaceuticals's current Net Cash per Share is MXN46.63, which is 97% above median its own 10-year median of 23.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vertex Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Vertex Pharmaceuticals (MEX:VRTX) is currently considered Fairly Valued. The stock's GF Value™ is MXN8,672.74, compared to a current price of MXN9,202.67 — trading 6.1% above its estimated fair value. The current Net Cash per Share is MXN46.63, which is 97% above median its 10-year median of 23.72. Vertex Pharmaceuticals' overall GF Score™ is 88/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Vertex Pharmaceuticals (MEX:VRTX), the current Net Cash per Share is MXN46.63 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vertex Pharmaceuticals (MEX:VRTX) Overvalued in 2026?
Based on GuruFocus' analysis, Vertex Pharmaceuticals stock appears to be overvalued.
The current stock price of MXN9,202.67 is trading 6.1% above its estimated GF Value™ of MXN8,672.74.
GuruFocus considers Vertex Pharmaceuticals to be Fairly Valued.
Key valuation signals for MEX:VRTX:
Net Cash per Share: MXN46.63 (97% above median its 10-year median of 23.72)
GF Value™: MXN8,672.74 vs. price of MXN9,202.67 (6.1% above fair value)
No single metric tells the full story. See the MEX:VRTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
88GF Score
Get the complete analysis for MEX:VRTX
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:VRTX has been successfully added to your 
